Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 2/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | ENPP2 | Q13822 | 2/20 | 0.38 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.38 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.38 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.38 |
| ▸ | JAK2 | O60674 | 3/20 | 0.37 |
| ▸ | JAK1 | P23458 | 3/20 | 0.37 |
| ▸ | PKM | P14618 | 1/20 | 0.37 |
| ▸ | BTK | Q06187 | 1/20 | 0.36 |
| ▸ | F2RL1 | P55085 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4761315 | 0.82 | NR1H2 (0.46) | USP30HPGDKDM4EALDH1A1ENPP2 | |
| SCHEMBL4814440 | 0.82 | USP30 (0.42) | USP30HPGDKDM4EALDH1A1ENPP2 | |
| SCHEMBL30730621 | 0.76 | GPR119 (0.53) | USP30ENPP2GPR119HDAC1HDAC2 | |
| SCHEMBL14635882 | 0.73 | GPR119 (0.48) | HPGDKDM4EALDH1A1GPR119PKM | |
| SCHEMBL6004484 | 0.72 | MEN1 (0.35) | ALDH1A1GPR119JAK2JAK1 | |
| SCHEMBL27161159 | 0.72 | GPR119 (0.41) | HPGDKDM4EALDH1A1GPR119 | |
| SCHEMBL27161150 | 0.72 | GPR119 (0.41) | HPGDKDM4EALDH1A1GPR119 | |
| SCHEMBL4721165 | 0.72 | ALDH1A1 (0.42) | HPGDKDM4EALDH1A1ENPP2GPR119 | |
| SCHEMBL6003951 | 0.71 | NR1H2 (0.47) | USP30HPGDENPP2HDAC1HDAC2 | |
| SCHEMBL31227749 | 0.71 | ALDH1A1 (0.50) | HPGDKDM4EALDH1A1GPR119 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060252807-A1 | Novel ortho-terphenyl inhibitors of p38 kinase and methods of treating inflammatory disorders | KALYPSYS, INC. | 2006-11-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060252807-A1 | Novel ortho-terphenyl inhibitors of p38 kinase and methods of treating inflammatory disorders | MAPK1, MAP3K1, MAPK4 | USP30 1591/4885HPGD 2186/4885KDM4E 3178/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.